NO952890D0 - Kombinasjonsbehandling for inhibisjon av bentap - Google Patents

Kombinasjonsbehandling for inhibisjon av bentap

Info

Publication number: NO952890D0
Authority: NO; Norway
Prior art keywords: bone loss; combination therapy; loss inhibition; inhibition; compound
Prior art date: 1994-07-22

Application number

NO952890A

Other languages

English (en)

Other versions

NO308194B1 (no

NO952890L (no

Inventor

Larry John Black

George Joseph Cullinan

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-22

Filing date

1995-07-20

Publication date

1995-07-20

1995-07-20 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-07-20 Publication of NO952890D0 publication Critical patent/NO952890D0/no

1996-01-23 Publication of NO952890L publication Critical patent/NO952890L/no

2000-08-14 Publication of NO308194B1 publication Critical patent/NO308194B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Control Of Motors That Do Not Use Commutators (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO952890A 1994-07-22 1995-07-20 Anvendelse av benzotiofener i kombinasjon med bisfosfonater for fremstilling av et preparat for inhibering av bentap, samt et farmasøytisk preparat NO308194B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27936394A	1994-07-22	1994-07-22

Publications (3)

Publication Number	Publication Date
NO952890D0 true NO952890D0 (no)	1995-07-20
NO952890L NO952890L (no)	1996-01-23
NO308194B1 NO308194B1 (no)	2000-08-14

Family

ID=23068631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO952890A NO308194B1 (no)	1994-07-22	1995-07-20	Anvendelse av benzotiofener i kombinasjon med bisfosfonater for fremstilling av et preparat for inhibering av bentap, samt et farmasøytisk preparat

Country Status (23)

Country	Link
US (1)	US20010051636A1 (no)
EP (1)	EP0693285B1 (no)
JP (1)	JPH0840911A (no)
KR (1)	KR960003726A (no)
CN (1)	CN1079671C (no)
AT (1)	ATE212846T1 (no)
AU (1)	AU693235B2 (no)
BR (1)	BR9503406A (no)
CA (1)	CA2154414A1 (no)
CZ (1)	CZ189195A3 (no)
DE (1)	DE69525291T2 (no)
DK (1)	DK0693285T3 (no)
ES (1)	ES2168336T3 (no)
HU (1)	HUT72754A (no)
IL (1)	IL114683A (no)
NO (1)	NO308194B1 (no)
NZ (1)	NZ272608A (no)
PL (1)	PL181304B1 (no)
PT (1)	PT693285E (no)
RU (1)	RU2149631C1 (no)
TW (1)	TW398975B (no)
UA (1)	UA41909C2 (no)
ZA (1)	ZA956029B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108882745A (zh) *	2016-03-10	2018-11-23	酶学技术有限公司	脂质组合物及其用途

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996016646A1 (en) *	1994-11-29	1996-06-06	Hoechst Marion Roussel, Inc.	Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
AU712711B2 (en) *	1994-11-29	1999-11-11	Hoechst Marion Roussel, Inc.	Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
EP0722727A1 (en) *	1995-01-20	1996-07-24	Eli Lilly And Company	Benzofuran derivatives for inhibiting uterine fibroid disease
US5554600A (en) *	1995-01-20	1996-09-10	Eli Lilly And Company	Methods for inhibiting endometriosis
US5512583A (en) *	1995-01-30	1996-04-30	Eli Lilly And Company	Methods of decreasing serum calcium levels
US6479517B1 (en) *	1995-02-28	2002-11-12	Eli Lilly And Company	Phosphorous-containing benzothiophenes
US5616571A (en) *	1995-06-06	1997-04-01	Merck & Co., Inc.	Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5958969A (en) *	1996-10-10	1999-09-28	Eli Lilly And Company	Benzo b!thiophene compounds, intermediates, formulations, and methods
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
US7005428B1 (en)	1998-06-11	2006-02-28	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en)	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1307206A2 (en) *	2000-07-19	2003-05-07	Eli Lilly And Company	Method for enhancing bone mineral density gain by administration of raloxifene
DE60111574T2 (de)	2001-01-23	2006-05-11	Gador S.A.	Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
US7309698B2 (en) *	2001-03-01	2007-12-18	Emisphere Technologies, Inc.	Compositions for delivering bisphosphonates
RU2192639C1 (ru) *	2001-04-05	2002-11-10	Дальневосточный государственный медицинский университет	Способ прогнозирования нарушений в постменопаузальном периоде
HRP20040906B1 (en) *	2002-05-10	2013-01-31	Hoffmann La Roche	Bisphosphonic acid for the treatment and prevention of ostreoporosis
TR200300510A2 (tr) *	2003-04-18	2004-11-22	Sanovel �La� Sanay� Ve T�Caret A.�.	Dağılan alendronat mikropartikül formülasyonu
DK3395339T3 (da) *	2003-09-12	2019-07-22	Amgen Inc	Hurtigt opløsende formulering af cinacalcet-hcl
KR100557086B1 (ko) *	2003-11-14	2006-03-03	한미약품 주식회사	랄록시펜과 비스포스포네이트의 상호 염
JP2007523184A (ja) *	2004-02-19	2007-08-16	テバファーマシューティカルインダストリーズリミティド	ラロキシフェン及びアレンドロネートの組合せを用いての改良された療法
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN1304401C (zh) *	2004-12-28	2007-03-14	浙江工业大学	一种阿伦膦酸的制备方法
PL1848414T3 (pl)	2005-02-03	2011-10-31	Wyeth Llc	Sposób leczenia nowotworu opornego na gefitinib
GB0506708D0 (en) *	2005-04-01	2005-05-11	Queen Mary & Westfield College	Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
AR057854A1 (es)	2005-11-04	2007-12-19	Wyeth Corp	Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es)	2008-06-17	2018-12-05	Wyeth Llc	Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CA2730715C (en)	2008-08-04	2013-10-01	Wyeth Llc	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
SG174382A1 (en)	2009-04-06	2011-11-28	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
US8703810B2 (en)	2010-06-10	2014-04-22	Seragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
SG11201403002RA (en)	2011-12-14	2014-07-30	Seragon Pharmaceuticals Inc	Fluorinated estrogen receptor modulators and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2914563A (en)	1957-08-06	1959-11-24	Wm S Merrell Co	Therapeutic composition
US3274213A (en)	1961-09-05	1966-09-20	Upjohn Co	Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
BE637389A (no)	1962-09-13
US4400543A (en)	1975-10-28	1983-08-23	Eli Lilly And Company	3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4323707A (en)	1975-10-28	1982-04-06	Eli Lilly And Company	Antifertility compounds
US4230862A (en)	1975-10-28	1980-10-28	Eli Lilly And Company	Antifertility compounds
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
DE3046719C2 (de)	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5139786A (en) *	1989-07-07	1992-08-18	Ciba-Geigy Corporation	Topical formulations
DE69023844T2 (de)	1989-09-06	1996-06-20	Merck & Co Inc	Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
DE69023906T2 (de)	1990-08-09	1996-04-11	Council Scient Ind Res	Benzopyrane und Verfahren zu deren Herstellung.
JPH04312526A (ja)	1991-04-09	1992-11-04	Fujisawa Pharmaceut Co Ltd	骨疾患治療剤
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0675723A4 (en) *	1992-12-23	1998-08-05	Merck & Co Inc	BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5591753A (en) *	1994-01-28	1997-01-07	Eli Lilly And Company	Combination treatment for osteoporosis

1995
- 1995-07-19 TW TW084107488A patent/TW398975B/zh not_active IP Right Cessation
- 1995-07-19 NZ NZ272608A patent/NZ272608A/xx active IP Right Revival
- 1995-07-19 ZA ZA956029A patent/ZA956029B/xx unknown
- 1995-07-19 UA UA95073400A patent/UA41909C2/uk unknown
- 1995-07-19 PL PL95309693A patent/PL181304B1/pl unknown
- 1995-07-20 HU HU9502193A patent/HUT72754A/hu unknown
- 1995-07-20 DE DE69525291T patent/DE69525291T2/de not_active Expired - Fee Related
- 1995-07-20 RU RU95114385A patent/RU2149631C1/ru active
- 1995-07-20 DK DK95305083T patent/DK0693285T3/da active
- 1995-07-20 EP EP95305083A patent/EP0693285B1/en not_active Expired - Lifetime
- 1995-07-20 NO NO952890A patent/NO308194B1/no not_active IP Right Cessation
- 1995-07-20 AT AT95305083T patent/ATE212846T1/de not_active IP Right Cessation
- 1995-07-20 AU AU27112/95A patent/AU693235B2/en not_active Ceased
- 1995-07-20 ES ES95305083T patent/ES2168336T3/es not_active Expired - Lifetime
- 1995-07-20 CZ CZ951891A patent/CZ189195A3/cs unknown
- 1995-07-20 KR KR1019950021267A patent/KR960003726A/ko not_active Ceased
- 1995-07-20 PT PT95305083T patent/PT693285E/pt unknown
- 1995-07-20 IL IL11468395A patent/IL114683A/en not_active IP Right Cessation
- 1995-07-21 CA CA002154414A patent/CA2154414A1/en not_active Abandoned
- 1995-07-21 CN CN95108916A patent/CN1079671C/zh not_active Expired - Fee Related
- 1995-07-21 BR BR9503406A patent/BR9503406A/pt not_active Application Discontinuation
- 1995-07-21 JP JP7185512A patent/JPH0840911A/ja not_active Withdrawn
2000
- 2000-03-08 US US09/520,737 patent/US20010051636A1/en not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108882745A (zh) *	2016-03-10	2018-11-23	酶学技术有限公司	脂质组合物及其用途
CN108882745B (zh) *	2016-03-10	2023-08-18	花臣有限公司	脂质组合物及其用途

Also Published As

Publication number	Publication date
HUT72754A (en)	1996-05-28
CZ189195A3 (en)	1996-06-12
NZ272608A (en)	2000-05-26
CN1119940A (zh)	1996-04-10
KR960003726A (ko)	1996-02-23
BR9503406A (pt)	1996-02-27
IL114683A0 (en)	1995-11-27
UA41909C2 (uk)	2001-10-15
DE69525291T2 (de)	2002-09-19
AU2711295A (en)	1996-02-01
EP0693285B1 (en)	2002-02-06
EP0693285A3 (en)	1998-05-06
ZA956029B (en)	1997-01-20
HU9502193D0 (en)	1995-09-28
NO308194B1 (no)	2000-08-14
PL181304B1 (pl)	2001-07-31
PL309693A1 (en)	1996-02-05
RU2149631C1 (ru)	2000-05-27
US20010051636A1 (en)	2001-12-13
DK0693285T3 (da)	2002-05-27
JPH0840911A (ja)	1996-02-13
EP0693285A2 (en)	1996-01-24
DE69525291D1 (de)	2002-03-21
TW398975B (en)	2000-07-21
CA2154414A1 (en)	1996-01-23
CN1079671C (zh)	2002-02-27
ATE212846T1 (de)	2002-02-15
NO952890L (no)	1996-01-23
PT693285E (pt)	2002-06-28
ES2168336T3 (es)	2002-06-16
IL114683A (en)	2001-06-14
AU693235B2 (en)	1998-06-25

Publication	Publication Date	Title
NO952890L (no)	1996-01-23	Kombinasjonsbehandling for inhibisjon av bentap
PH30032A (en)	1996-11-08	Methods for inhibiting bone loss
PL303937A1 (en)	1995-01-09	Application of an antiestrogen compound and pharmaceutical agent
MY118151A (en)	2004-09-30	Pharmaceutical formulations containing voriconazole.
PT998287E (pt)	2003-09-30	Utilizacao de levobupivacaina
DK0652000T3 (da)	2001-11-12	Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et lægemiddel til inhibering af angiogenese og angiogene sygdomme
HUP0100024A3 (en)	2002-12-28	Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
IL84844A0 (en)	1988-06-30	Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
GR3015014T3 (en)	1995-05-31	Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
PL322526A1 (en)	1998-02-02	Azathiopyrin compositions for intracolic administration
FI962685A7 (fi)	1996-08-28	2,3-diaryyli-1-bentsopyraanijohdannaisten käyttö lääkkeen valmistamise ksi luukadon ja osteoporoosin hoitamiseksi ja estämiseksi
DK0629400T3 (da)	2000-02-14	Idebenon-holdige præparater til behandling af Alzheimer's syge
EP0744176A3 (en)	2002-05-15	Methods for inhibiting bone loss
IL105475A (en)	1997-06-10	PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
IL111580A (en)	1999-10-28	Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
IL111579A (en)	1999-10-28	Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating desynchronization disorders
ITTO920656A1 (it)	1994-01-31	Sedia per operativita' chirurgica.
ITBO910227A1 (it)	1992-12-26	Pinza per estrazioni dentarie.
ITPD910046A0 (it)	1991-03-06	Pinza per l'estrazione dentale
ITTO920146A1 (it)	1993-08-25	Medica confezione per intervento urologico.

Legal Events

Date	Code	Title	Description
2003-03-10	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN JANUARY 2003